- Previous Close
5.850 - Open
5.700 - Bid 5.680 x --
- Ask 5.700 x --
- Day's Range
5.640 - 5.820 - 52 Week Range
4.130 - 7.980 - Volume
626,500 - Avg. Volume
2,186,732 - Market Cap (intraday)
4.572B - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-0.550 - Earnings Date Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.35
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. It had various drug assets in its portfolio. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
www.ocumension.comRecent News: 1477.HK
View More
Performance Overview: 1477.HK
Trailing total returns as of 10/24/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1477.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1477.HK
View MoreValuation Measures
Market Cap
4.70B
Enterprise Value
3.65B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.32
Price/Book (mrq)
1.55
Enterprise Value/Revenue
10.79
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-104.01%
Return on Assets (ttm)
-7.01%
Return on Equity (ttm)
-11.70%
Revenue (ttm)
310.29M
Net Income Avi to Common (ttm)
-322.73M
Diluted EPS (ttm)
-0.550
Balance Sheet and Cash Flow
Total Cash (mrq)
972.91M
Total Debt/Equity (mrq)
0.55%
Levered Free Cash Flow (ttm)
-420.12M
Research Analysis: 1477.HK
View MoreCompany Insights: 1477.HK
1477.HK does not have Company Insights